Every pharma company I cover has U.S. production so tariffs are more bark than bite: BMO’s Seigerman

Evan Seigerman, BMO Capital Markets head of healthcare research, joins ‘Closing Bell’ to discuss President Trump’s latest tariff announcement on pharmaceutical companies, where execution needs to happen and much more.